Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCN-107
- Development stage
- Unknown
- Lead developer
- Scienture Holdings
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
SCN-107 is a long-acting injectable formulation of bupivacaine, a local anesthetic, being developed by Scienture Holdings (formerly TRxADE HEALTH) for the management of post-operative pain. The formulation utilizes a novel polymer-based microsphere suspension designed to provide extended drug release, offering non-opioid analgesia for a period of 5 to 7 days following surgery. It is intended for postsurgical local and regional analgesia with a rapid onset of action, aiming to provide a long-lasting alternative to traditional pain management strategies and reduce the reliance on opioids in the post-operative setting.
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on SCN-107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCN-107.